Nicox presents new analysis from the NCX 470 Mont Blanc trial

French ophthalmic drug specialist Nicox (Euronext Growth Paris: FR0013018124) has provided details of a poster presentation highlighting additional pre-planned analysis from the NCX 470 Mont Blanc Phase III clinical trial at the 2025 American Glaucoma Society (AGS) Annual Meeting. The company also provided an update on NCX 470 development.

“These data provide another example of where NCX 470 is differentiated from the standard-of-care for intraocular pressure reduction, latanoprost. In this analysis, we demonstrated that more patients achieve intraocular pressure of less than or equal to 18 mmHg on NCX 470 than on latanoprost. In addition, the mean percentage reduction in intraocular pressure was greater in patients on NCX 470 compared to those on latanoprost.” said Doug Hubatsch, chief scientific officer of Nicox. “We also look forward to announcing the results of the Whistler trial, investigating the mechanism of action of NCX 470, shortly, and the second pivotal Phase III trial, Denali, in Q3 of this year,” he noted.

A statistically-significant greater proportion of eyes treated with NCX 470 0.1% achieved mean diurnal IOPs of ≤18 mmHg compared to those in the latanoprost 0.005% group in this analysis of the multinational Phase III Mont Blanc clinical trial. Additionally, greater mean percent IOP reductions from baseline were seen in the eyes treated with NCX 470 than in eyes treated with latanoprost.